NFXF Blog

Learn about CDMRP funding opportunities for research on Fragile X-associated conditions and disorders, including application deadlines, key award mechanisms, and how the NFXF supports researchers.

Shionogi provides updates on the EXPERIENCE adult and adolescent studies in Fragile X syndrome.

This research looks at social participation in children with Fragile X syndrome, including key barriers, gender differences, and practical ways families, schools, and communities can support inclusion and engagement.

A Message from Harmony Biosciences about the RECONNECT Trial and the conclusion of its Open Label Extension (OLE) program

Mirum Pharmaceuticals has officially enrolled the first participant in its BLOOM Phase 2 clinical study evaluating MRM-3379, a potential new treatment for Fragile X syndrome (FXS).

This research looks at how a child’s level of intellectual disability (ID) — meaning how much their thinking and learning abilities are affected — relates to the types of behavioral challenges they experience if they have Fragile X syndrome (FXS).

CONNECTA Therapeutics is taking a new approach to Fragile X syndrome treatment by boosting the brain’s natural ability to reconnect and adapt.

Harmony Biosciences recently announced results from its Phase 3 RECONNECT study of ZYN002, a cannabidiol (CBD) gel being tested for Fragile X syndrome.

Bowen’s FX Therapeutics, a company with roots in the Fragile X community, is advancing efforts toward a future protein replacement therapy.